Literature DB >> 23110915

Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis.

Maria Unni Rømer1, Sune Boris Nygård, Ib Jarle Christensen, Signe Lykke Nielsen, Kirsten Vang Nielsen, Sven Müller, David Hersi Smith, Ben Vainer, Hans Jørgen Nielsen, Nils Brünner.   

Abstract

PURPOSE: A Topoisomerase 1 (Top1) poison is frequently included in the treatment regimens for metastatic colorectal cancer (mCRC). However, no predictive biomarkers for Top1 poisons are available. We here report a study on the TOP1 gene copy number in CRC patients and its association with patient prognosis and tumor cell proliferation. EXPERIMENTAL
DESIGN: The study included TOP1 and CEN-20 fluorescence in situ hybridization (FISH) analyses on formalin fixed paraffin embedded (FFPE) tissue sections from 154 stage III CRC chemonaïve patients. The frequencies of aberration in the TOP1 gene copy number, the CEN-20 copy number and the TOP1/CEN-20 ratio were analyzed and associated with overall survival (OS), time to recurrence (TTR) and in a subgroup analysis of rectal cancer patients only with time to local recurrence (LR in RC). Moreover, the TOP1 and CEN-20 copy numbers were correlated with the tumor Ki67 proliferation index.
RESULTS: 35.7% of the tumors had an increased TOP1 copy number above 4n gene copies per cell and 28.6% and 9.7% had a TOP1/CEN-20 ratio ≥1.5 or ≥2.0, respectively. The TOP1 copy number and the TOP1/CEN-20 ratios were separately added into multivariate analyses as continuous variables, in which also age, gender, primary tumor location and Ki67 status were added as covariates. In contrast to the TOP1/CEN-20 ratio, the TOP1 copy number was significantly associated with OS (HR: 0.62; 95% CI: 0.42-0.90; p = 0.01). Neither the TOP1 copy number nor the ratio was significantly associated with TTR and only the TOP1/CEN-20 ratio was significantly associated with LR in RC (HR: 0.25; 95% CI: 0.08-0.83; p = 0.02). No significant correlation was found between the TOP1 copy number and proliferation, while a weak and inverse correlation between the CEN-20 copy number and proliferation was observed.
CONCLUSIONS: This study showed that increased TOP1 gene copy numbers are frequent findings in cancer cells in stage III CRC tumors but unrelated to the proliferative status of the tumors. The association with prognosis is important to consider when planning and analyzing future studies investigating TOP1 as a potential predictive biomarker for Top1 poisons.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23110915      PMCID: PMC5528401          DOI: 10.1016/j.molonc.2012.09.001

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  28 in total

1.  Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.

Authors:  Miriam Koopman; Ninja F Antonini; Joep Douma; Jaap Wals; Aafke H Honkoop; Frans Lg Erdkamp; Robert S de Jong; Cees J Rodenburg; Gerard Vreugdenhil; Olaf Jl Loosveld; Aart van Bochove; Harm Am Sinnige; Geert-Jan M Creemers; Margot Et Tesselaar; Peter H Th J Slee; Marjon Jbp Werter; Linda Mol; Otilia Dalesio; Cornelis Ja Punt
Journal:  Lancet       Date:  2007-07-14       Impact factor: 79.321

2.  REporting recommendations for tumor MARKer prognostic studies (REMARK).

Authors:  Lisa M McShane; Douglas G Altman; Willi Sauerbrei; Sheila E Taube; Massimo Gion; Gary M Clark
Journal:  Breast Cancer Res Treat       Date:  2006-08-24       Impact factor: 4.872

3.  TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity.

Authors:  Maria Unni Rømer; Niels Frank Jensen; Signe Lykke Nielsen; Sven Müller; Kirsten Vang Nielsen; Hans Jørgen Nielsen; Nils Brünner
Journal:  Scand J Gastroenterol       Date:  2012-01       Impact factor: 2.423

4.  retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.

Authors:  Ann S Knoop; Helle Knudsen; Eva Balslev; Birgitte B Rasmussen; Jens Overgaard; Kirsten V Nielsen; Andreas Schonau; Katrín Gunnarsdóttir; Karen E Olsen; Henning Mouridsen; Bent Ejlertsen
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

5.  Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer.

Authors:  Michal Sheffer; Manny D Bacolod; Or Zuk; Sarah F Giardina; Hanna Pincas; Francis Barany; Philip B Paty; William L Gerald; Daniel A Notterman; Eytan Domany
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-09       Impact factor: 11.205

6.  Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

Authors:  Eric Van Cutsem; Roberto Labianca; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Claire Topham; Josep Tabernero; Thierry André; Alberto F Sobrero; Enrico Mini; Richard Greil; Francesco Di Costanzo; Laurence Collette; Laura Cisar; Xiaoxi Zhang; David Khayat; Carsten Bokemeyer; Arnaud D Roth; David Cunningham
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

7.  Relationship of gene expression and chromosomal abnormalities in colorectal cancer.

Authors:  Dafna Tsafrir; Manny Bacolod; Zachariah Selvanayagam; Ilan Tsafrir; Jinru Shia; Zhaoshi Zeng; Hao Liu; Curtis Krier; Robert F Stengel; Francis Barany; William L Gerald; Philip B Paty; Eytan Domany; Daniel A Notterman
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

8.  CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity.

Authors:  Ron Firestein; Adam J Bass; So Young Kim; Ian F Dunn; Serena J Silver; Isil Guney; Ellen Freed; Azra H Ligon; Natalie Vena; Shuji Ogino; Milan G Chheda; Pablo Tamayo; Stephen Finn; Yashaswi Shrestha; Jesse S Boehm; Supriya Jain; Emeric Bojarski; Craig Mermel; Jordi Barretina; Jennifer A Chan; Jose Baselga; Josep Tabernero; David E Root; Charles S Fuchs; Massimo Loda; Ramesh A Shivdasani; Matthew Meyerson; William C Hahn
Journal:  Nature       Date:  2008-09-14       Impact factor: 49.962

9.  Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.

Authors:  Michael S Braun; Susan D Richman; Philip Quirke; Catherine Daly; Julian W Adlard; Faye Elliott; Jennifer H Barrett; Peter Selby; Angela M Meade; Richard J Stephens; Mahesh K B Parmar; Matthew T Seymour
Journal:  J Clin Oncol       Date:  2008-06-01       Impact factor: 44.544

10.  Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.

Authors:  Ioannis Kostopoulos; Vasilios Karavasilis; Maria Karina; Mattheos Bobos; Nikolaos Xiros; George Pentheroudakis; Georgia Kafiri; Pavlos Papakostas; Eleni Vrettou; George Fountzilas
Journal:  BMC Cancer       Date:  2009-09-24       Impact factor: 4.430

View more
  12 in total

1.  Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.

Authors:  Ida Marie Heeholm Sønderstrup; Sune Boris Nygård; Tim Svenstrup Poulsen; Dorte Linnemann; Jan Stenvang; Hans Jørgen Nielsen; Jiri Bartek; Nils Brünner; Peter Nørgaard; Lene Riis
Journal:  Mol Oncol       Date:  2015-03-04       Impact factor: 6.603

2.  Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis.

Authors:  Maria Unni Rømer; Sune Boris Nygård; Ib Jarle Christensen; Signe Lykke Nielsen; Kirsten Vang Nielsen; Sven Müller; David Hersi Smith; Ben Vainer; Hans Jørgen Nielsen; Nils Brünner
Journal:  Mol Oncol       Date:  2012-10-11       Impact factor: 6.603

3.  Measuring ERCC1 protein expression in cancer specimens: validation of a novel antibody.

Authors:  David Hersi Smith; Anne-Marie Kanstrup Fiehn; Louise Fogh; Ib Jarle Christensen; Tine Plato Hansen; Jan Stenvang; Hans Jørgen Nielsen; Kirsten Vang Nielsen; Jane Preuss Hasselby; Nils Brünner; Sussie Steen Jensen
Journal:  Sci Rep       Date:  2014-03-07       Impact factor: 4.379

Review 4.  Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development.

Authors:  Jan Stenvang; Iben Kümler; Sune Boris Nygård; David Hersi Smith; Dorte Nielsen; Nils Brünner; José M A Moreira
Journal:  Front Oncol       Date:  2013-12-25       Impact factor: 6.244

5.  Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.

Authors:  Jesper Andreas Palshof; Estrid Vilma Solyom Høgdall; Tim Svenstrup Poulsen; Dorte Linnemann; Benny Vittrup Jensen; Per Pfeiffer; Line Schmidt Tarpgaard; Nils Brünner; Jan Stenvang; Mette Yilmaz; Dorte Lisbet Nielsen
Journal:  BMC Cancer       Date:  2017-01-11       Impact factor: 4.430

6.  Genome wide analysis of chromosomal alterations in oral squamous cell carcinomas revealed over expression of MGAM and ADAM9.

Authors:  Vui King Vincent-Chong; Arif Anwar; Lee Peng Karen-Ng; Sok Ching Cheong; Yi-Hsin Yang; Padmaja Jayaprasad Pradeep; Zainal Ariff Abdul Rahman; Siti Mazlipah Ismail; Zuraiza Mohamad Zaini; Narayanan Prepageran; Thomas George Kallarakkal; Anand Ramanathan; Nur Aaina Binti Mohd Mohayadi; Nurul Shielawati Binti Mohamed Rosli; Wan Mahadzir Wan Mustafa; Mannil Thomas Abraham; Keng Kiong Tay; Rosnah Binti Zain
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

7.  Mechanisms of topoisomerase I (TOP1) gene copy number increase in a stage III colorectal cancer patient cohort.

Authors:  David Hersi Smith; Ib Jarle Christensen; Niels Frank Jensen; Bo Markussen; Maria Unni Rømer; Sune Boris Nygård; Sven Müller; Hans Jørgen Nielsen; Nils Brünner; Kirsten Vang Nielsen
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

8.  Integrated analysis of copy number variation and genome-wide expression profiling in colorectal cancer tissues.

Authors:  Nur Zarina Ali Hassan; Norfilza Mohd Mokhtar; Teow Kok Sin; Isa Mohamed Rose; Ismail Sagap; Roslan Harun; Rahman Jamal
Journal:  PLoS One       Date:  2014-04-02       Impact factor: 3.240

9.  An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort.

Authors:  David Hersi Smith; Ib Jarle Christensen; Niels Frank Jensen; Bo Markussen; Sven Müller; Hans Jørgen Nielsen; Nils Brünner; Kirsten Vang Nielsen
Journal:  BMC Cancer       Date:  2013-10-21       Impact factor: 4.430

10.  Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer.

Authors:  Yang Bai; Liang-Dong Li; Jun Li; Xin Lu
Journal:  J Ovarian Res       Date:  2016-06-18       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.